Laropiprant

From Wikipedia, the free encyclopedia

Laropiprant
Systematic (IUPAC) name
(-)-[(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
Identifiers
CAS number	571170-77-9
ATC code	?
PubChem	?
Chemical data
Formula	C21H19ClFNO4S
Mol. mass	435.90 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Laropiprant (pINN; codenamed MK-0524A) is an investigational treatment for hypercholesterolemia. It is a prostanoid DP1 receptor antagonist. It will be marketed by Merck & Co. as a combination with niacin and will be sold under the tradenames Cordaptive and Tredaptive.

v • d • e Lipid modifying agents (C10) Statins Atorvastatin • Cerivastatin‡ • Fluvastatin • Lovastatin • Mevastatin • Pitavastatin • Pravastatin • Rosuvastatin • Simvastatin Fibrates Clofibrate‡ • Bezafibrate • Aluminium clofibrate • Gemfibrozil • Fenofibrate • Simfibrate • Ronifibrate • Ciprofibrate • Etofibrate • Clofibride Bile acid sequestrants Colestyramine • Colestipol • Colextran • Colesevelam Niacin and derivatives Niceritrol • Niacin • Nicofuranose• Aluminium nicotinate• Nicotinyl alcohol • Acipimox CETP inhibitors Anacetrapib† • Torcetrapib§ Combinations Niacin/lovastatin • Niacin/simvastatin • Ezetimibe/simvastatin Other Dextrothyroxine • Probucol • Tiadenol • Benfluorex • Meglutol • Omega-3-triglycerides • Magnesium pyridoxal 5-phosphate glutamate • Policosanol • Ezetimibe • Laropiprant†, Lapaquistat§ †Undergoing clinical trials. ‡Withdrawn from market. §Development terminated.